We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Predictors of long-term remission in patients with Graves' disease: a single center experience.
- Authors
Anagnostis, Panagiotis; Adamidou, Fotini; Polyzos, Stergios; Katergari, Simoni; Karathanasi, Eleni; Zouli, Chrisanthi; Panagiotou, Athanasios; Kita, Marina
- Abstract
Antithyroid drugs (ATDs) remain the first-line therapy in patients with Graves' disease (GD), despite a high relapse rate. The purpose of this study was to identify the predictors of remission in patients with GD treated with ATDs-retrospective study at an endocrine referral service in Northern Greece. Two-hundred and eleven patients met the study's criteria. Females ( p = 0.049), non-smokers ( p = 0.017), patients without ophthalmopathy ( p = 0.033), and those developing pharmaceutical hypothyroidism ( p = 0.018) experienced longer duration of remission. Duration of remission was positively associated with therapy duration ( r = 0.151, p = 0.030), maximum TSH levels during ( r = 0.241, p = 0.001), at the end ( r = 0.280, p < 0.001) and 3 months after therapy ( r = 0.341, p = 0.003). There was a negative association with free T4 (FT4) ( r = −0.426, p < 0.001) and free triiodothyronine (FT3) ( r = −0.467, p = 0.038) levels at 6 months after ATDs discontinuation. In multiple-regression analysis, only duration of the first ATDs course for more than 24 months independently predicted duration of remission. Female gender, non-smoking, the absence of orbitopathy, treatment duration, pharmaceutical hypothyroidism, higher TSH levels during, at the end and 3 months after ATDs discontinuation, and lower FT4 and FT3 levels 6 months after therapy were associated with longer duration of remission. However, only duration of ATDs therapy for more than 24 months independently predicted predict long-term remission in GD.
- Subjects
GRAVES' disease; DISEASE remission; THYROID antagonists; ENDOCRINOLOGY; HYPOTHYROIDISM; TRIIODOTHYRONINE; THERAPEUTICS
- Publication
Endocrine (1355008X), 2013, Vol 44, Issue 2, p448
- ISSN
1355-008X
- Publication type
Article
- DOI
10.1007/s12020-013-9895-0